Gingko Bioworks Leaders Get $4.1 Million Settlement Approved

Gingko Bioworks Holdings Inc. will benefit from a derivative suit settlement between investors and members of its leadership for $4.1 million, corporate reforms, and the termination of certain contracts, a federal court ruled.

Judge Kandis A. Westmore granted final approval to the accord Dec. 19 in the US District Court for the Northern District of California. “The lack of any shareholder objection, including from institutional holders, weighs heavily in favor of approval,” she said.

• A pair of investor suits on behalf of the company said Gingko was overvalued in its merger with a special purpose acquisition company in 2021
• The ...